# Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

> **NCT01589237** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 38 (actual)

## Conditions studied

- Familial Chylomicronemia Syndrome (FCS) (HLP Type I)

## Interventions

- **DRUG:** LCQ908

## Key facts

- **NCT ID:** NCT01589237
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Interim analysis suggested that size of benefit anticipated from continued participation of patients in Part B no longer supported trial extension beyond Part A
- **Last updated:** 2016-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01589237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01589237, "Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01589237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*